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Absolute	configuration	of	the	antimalarial	erythro-mefloquine	–	
Vibrational	Circular	Dichroism	and	X-ray	diffraction	studies	of	
mefloquine	and	its	thiourea	derivative	
M.	Kohout*a,	J.	Vandenbussche,b	A.	Rollerc,	J.	Tůmaa,	J.	Bogaertsd,	P.	Bultinckb,	W.	Herrebout*d,	
and	W.	Lindnere	
The	 long-standing	 discussion	 of	 the	 absolute	 configuration	 of	
erythro-mefloquine	 is	 resolved	 using	 a	 combination	 of	
experimental	 and	 calculated	 Vibrational	 Circular	 Dichroism	
spectroscopy.	 This	 assignment	 of	 one	 of	 the	 most	 important	
antimalarials	 is	 further	 confirmed	 by	 x-ray	 diffraction-based	
structure	elucidation	of	thiourea	derivates.		
Malaria	remains	one	of	the	most	devastating	diseases	in	the	world	
responsible	 for	many	hundreds	of	thousands	of	deaths	a	year	as	a	
consequence	 of	 nearly	 200	million	 infections.1	Most	 deaths	 occur	
among	children	living	in	Africa	where	a	child	dies	every	minute	from	
malaria.	Although	some	elementary	precautions	help	to	reduce	the	
risk,	antimalarial	medicines	can	also	be	used	to	prevent	malaria	or	
as	 treatment	 of	 those	 already	 infected.	 Moreover,	 the	 recent	
outbreak	 of	 Ebola	 in	 Africa	 strengthens	 the	 pressing	 necessity	 of	
malaria	 prevention	 as	 both	 deadly	 diseases	 share	 the	 same	 initial	
symptoms.	 Establishing	 that	 a	person	 is	 a	 victim	of	 ebola	 requires	
ruling	out	malaria.	
One	 of	 the	 drugs	 used	 in	 both	 prevention	 and	 as	 standard	
medication	 in	 malaria	 chemoprophylaxis	 and	 treatment	 is	 rac-
erythro-mefloquine	 hydrochloride,	 commercialized	 as	 Lariam®2.	
This	molecule	(see	figure	1)	is	known	to	be	optically	active	and	both	
(+)-erythro-mefloquine	 and	 (-)-erythro-mefloquine	 have	 been	
investigated.	 Its	 stereochemistry	 not	 only	 influences	 the	
antimalarial	activity3,4	of	the	compound	but	also	results	in	different	
side	 effects	 for	 the	 respective	 enantiomers.5,6	 While	 (+)-erythro-
mefloquine	 was	 found	 to	 be	 more	 active	 against	 various	 malaria	
species,7	 the	 (-)-erythro-mefloquine	 shows	 longer	 plasma	 half-life	
than	 the	 (+)-enantiomer	 as	 well	 as	 higher	 affinity	 to	 adenosine	
receptors	 leading	 to	 various	 neuropsychiatric	 adverse	 effects.5	
Despite	 the	 above	 mentioned	 impact	 of	 malaria	 on	 the	 lives	 of	
billions	 and	 the	 necessity	 for	 proper	 treatment	 medication,	 the	
assignment	 of	 the	 absolute	 configuration	 has	 been	 quite	
problematic	 despite	 the	 differences	 in	 activity	 and	 side	 effects	 of	
(+)-and	 (-)-erythro-mefloquine	 have	 been	 studied	 in	 detail.8,9	 The	
first	 assignment	 was	 based	 on	 electronic	 circular	 dichroism	 (ECD)	
data,	 and	 the	 authors	 tentatively	 assigned	 the	 absolute	
configuration	of	the	(+)-enantiomer	as	(11R,	12S).10	This	assignment	
was	 later	 disproved	 by	 anomalous	 X-ray	 diffraction	 (XRD)	 of	 (-)-
mefloquine	 hydrochloride	 for	 which	 the	 absolute	 configuration	
(11R,	12S)	was	derived	and	hence	infers	the	(+)-enantiomer	has	the	
(11S,	 12R)	 configuration.11	 This	 	 claim	 was	 confirmed	 by	 two	
different	approaches	using	residual	dipolar	coupling	enhanced	NMR	
spectroscopy	 in	 combination	 with	 optical	 rotational	 dispersion,12	
and	 by	 XRD	 analysis	 of	 Mosher	 amides.13	 The	 experimental	 data	
reported	 in	 Refs	 9	 and	 10	 in	 turn	 contradict	 data	 derived	 from	
stereoselective	 total	 syntheses	 that,	 until	 very	 recently,	 confirmed	
the	 results	 of	 the	 ECD	 measurement.14-17	 The	 most	 recent	
stereoselective	 approaches	 based	 on	 Pd-catalyzed	 reaction,	
domino-Sonogashira-6π-electrocyclization	 and	 Heck	 coupling	
followed	 by	 Sharpless	 dihydroxylation	 not	 only	 provided	
stereoselectively	 all	 four	 stereoisomers	 of	 mefloquine	 but	 also	
establish	 the	 absolute	 configuration	 of	 (+)-erythro-mefloquine	 as	
(11S,	 12R)	 and	 (-)-erythro-mefloquine	 as	 (11R,	 12S).18-20	 Such	
ambiguity	in	determining	the	absolute	configuration	of	a	crystalline	
organic	 compound	 by	 that	 many	 physical	 as	 well	 as	 asymmetric	
synthetic	 methods	 is	 puzzling,	 in	 particular,	 for	 an	 important	 and	
widely	 used	 drug.	We	 therefore	 set	 out	 to	 establish	 the	 absolute	
configuration	 of	 both	 enantiomers	 using	 Vibrational	 Circular	
Dichroism	(VCD).	Moreover,	 in	order	to	 independently	confirm	the	
VCD	based	results,	a	heavy	atom	labeled	mefloquine	derivative	was	
synthesized	(see	ESI).	The	applied	enantiopure	thiourea	label	allows	
for	 effective	 crystallization	 and	 absolute	 configuration	
determination	using	XRD.	
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Figure	 1.	 	 	 Structures	 of	 (+)-erythro-mefloquine	 (1),	 (-)-erythro-
mefloquine	 (2),	 (-)-erythro-N-(N-allylthiocarbamoyl)	mefloquine	 (3)	
and	(+)-erythro-N-(N-allylthiocarbamoyl)	mefloquine	(4).	
As	ECD,	VCD	is	a	chiroptical	spectroscopy,	relying	on	the	difference	
in	 absorption	 between	 left	 and	 right	 handed	 circular	 polarized	
infrared	(IR)	radiation.	As	a	consequence,	VCD	offers	the	structural	
specificity	 of	 solution-based	 IR	 spectroscopy	 combined	 with	
stereochemical	 sensitivity.	 In	 general,	 a	 VCD	 analysis	 requires	 (1)	
the	 measurement	 of	 both	 IR	 and	 VCD	 spectra	 of	 a	 sample	 in	
solution	with	unknown	AC	and	 (2)	a	quantum	chemical	 simulation	
of	these	spectra	for	a	specific	AC.	Due	to	the	differential	nature	of	
VCD	 spectra,	 both	 positive	 and	 negative	 bands	 can	 occur.	 This	
means	 that	 for	 a	 specific	 wave	 number,	 if	 the	 (+)	 enantiomer	
preferentially	 absorbs	 the	 right	 circularly	 polarized	 light,	 the	 (-)	
enantiomer	preferentially	absorbs	the	left	circularly	polarized	light.	
The	resulting	spectra,	however,	are	not	so	easy	linked	to	a	specific	
AC,	 hence	 the	 need	 for	 quantum	 chemically	 computed	 spectra.	
These	can	be	computed	for	any	AC	and	by	carefully	establishing	the	
agreement	 between	 every	 computed	 spectrum	 with	 an	
experimental	 one,	 the	 AC	 of	 the	 experimental	 sample(s)	 is	
obtained.	21,22	As	reported	above,	ECD	has	been	used	previously	but	
did	 not	 allow	 to	 conclusively	 establish	 the	 AC.	 One	 of	 the	 main	
advantages	of	VCD	as	opposed	to	ECD	is	that	vibrational	transitions	
are	 studied	 of	 which	 there	 are	 many	 more	 than	 the	 electronic	
transitions	that	underlie	ECD.21,22	
It	 is	 important	 to	note	 that	mefloquine	and	 its	 thiourea-derivative	
each	 contain	 2	 chiral	 centers,	 and	 hence,	 for	 a	 complete	 VCD	
analysis,	this	would	require	the	simulation	of	the	VCD	spectra	of	all	
diastereomers.	 Obviously,	 the	 elucidation	 of	 the	 molecular	 AC	 of	
the	 sample	 can	 then	 only	 be	 achieved	 when	 the	 computed	 VCD	
spectra	of	the	diastereomers	are	sufficiently	different.	Fortunately,	
however,	 it	 is	 known	 that	 mefloquine	 in	 Lariam	 has	 the	 erythro-
configuration	and,	 thus,	 the	AC	either	corresponds	 to	 (11S,12R)	or	
(11R,12S).	 	 One	 of	 the	 issues	 that	 needs	 to	 be	 dealt	 with	 when	
modelling	 VCD	 spectra	 is	 that	 the	 resulting	 spectra	 depend	
significantly	 on	 the	 molecular	 conformation.	 As	 the	 present	
molecules	 are	 expected	 to	 have	 a	 fairly	 complicated	 potential	
energy	 surface	 (PES),	 it	 is	 of	 prime	 importance	 that	 all	 significant	
molecular	 geometries	 are	 properly	 accounted	 for.	 This	 is	 done	 by	
conformational	analysis	in	which	all	important	(local)	minima	on	the	
PES	 are	 identified.	 For	 all	 these	 the	 IR	 and	 VCD	 spectra	 are	
computed	and	a	molecular	IR	and	VCD	spectrum	is	computed	as	an	
enthalpy	based	Boltzmann	average	over	all	conformations	and	their	
spectra.	As	exploring	the	PES	with	ab	initio	methods	from	the	start	
is	computationally	too	demanding,	a	first	conformational	analysis	is	
performed	 at	 the	 molecular	 mechanics	 level.	 Three	 different	
software	packages	were	used	with	 the	molecular	mechanics	 force	
fields	 given	 between	 brackets:	 HyperChem16	 (mm+23),	 Conflex24-26	
(MMFF94S27)	 and	 Spartan28	 (MMFF9429	 and	 SYBYL30)	 each	 with	
their	specific	algorithms	for	PES	exploration.	The	resulting	minimum	
energy	 structures	 were	 then	 gathered	 and	 redundancies	
eliminated.	 The	 remaining	 conformations	 were	 further	 optimized	
using	 the	 B3LYP	 functional	 and	 6-31G*	 basis	 set	 including	 a	
Polarizable	 Continuum	 Model	 (PCM)	 solvent	 model.	 In	 the	 next	
phase,	 the	 structures	 were	 further	 optimized	 using	 the	 cc-pVDZ	
basis	set	and	B3LYP	functional	with	a	PCM	model.	PCM	refers	to	the	
standard	 self-consistent	 reaction	 field	 model	 used	 to	 account	 for	
solute-solvent	 interactions.31	 Geometry	 optimizations	 and	
calculations	of	the	IR	and	VCD	spectral	data	were	performed	using	
Gaussian09.32	 The	 Boltzmann	 weighted	 IR	 and	 VCD	 spectra	 for	
mefloquine	and	N-(N-allylthiocarbamoyl)	mefloquine	were	obtained	
taking	in	to	account	42	and	23	unique	conformations,	respectively.	
The	 experimentally	 obtained	 VCD	 spectra	 for	 (+)-erythro-
mefloquine	and	 the	calculated	one	 for	 the	 (11S,12R)-configuration	
are	 shown	 in	 Figure	 2.	 Bands	 are	 labeled	 by	 performing	 manual	
assignment	 of	 the	 bands	 in	 coherence	 with	 the	 IR	 spectra.	 Even	
though	 a	 few	 significant	 features	 cannot	 be	 reproduced	 (e.g.	 the	
region	between	1160-1200	cm−1	and	 the	 strong	negative	bands	at	
1070	and	1280	cm−1),	Figure	2	clearly	shows	very	good	agreement	
between	the	spectra.	Based	on	the	visual	agreement,	the	AC	of	(+)-
erythro-mefloquine	 can	 clearly	 be	 assigned	 as	 (11S,12R).	
	
	
Figure	 2.	 Experimental	 VCD	 spectrum	 for	 (+)-erythro-mefloquine	
(lower	 panel)	 and	 the	 computed	 one	 for	 the	 (11S,12R)-absolute	
configuration	 (upper	 panel).	 The	 spectrum	 has	 been	 frequency	
scaled	with	 a	 factor	σ which	 yields	 a maximal	 similarity	 between	
the	computed	and	experimental	IR	spectra.	
To	avoid	personal	 bias	 in	manual	 assignments,	 it	 is	 recommended	
to	 establish	 the	 agreement	 between	 experimental	 and	 theoretical	
spectra	 using	 numerical	 methods.	 To	 this	 end	 we	 used	 the	
statistical	validation	approach	by	Vandenbussche	et	al.,33	the	reader	
is	referred	to	this	work	for	full	technical	details.	
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Figure	3.	𝑹𝐱,𝐞𝐱𝐩𝐕𝐂𝐃 	versus	𝑹𝐱,𝐜𝐚𝐥𝐜𝐕𝐂𝐃 	scatter	diagram	for	the	measured	(+)-
erythro-mefloquine	 spectrum	 and	 the	 computed	 (11S,12R)-
mefloquine	 spectrum.	 Blue	 datapoints	 represent	 random	 spectra.	
The	red	datapoint	represents	the	quanum	chemical	spectrum	which	
has	 a	 100%	 similarity	 with	 respect	 to	 itself	 and	 a	 similarity	 of	 R	
(VCD)	with	respect	to	the	experiment.	The	black	line	is	obtained	by	
orthogonal	 regression.	 The	 area	 between	 the	 green	 lines	 contains	
99%	of	the	datapoints.	
Figure	 3	 shows	 the	 resulting	 plot	 which	 is	 to	 be	 interpreted	 as	
follows.	 A	 very	 large	 number	 of	 spectra	 are	 computationally	
generated	 although	 only	 one	 (the	 red	 dot	 in	 figure	 3)	 originates	
from	 a	 quantum	 chemical	 and	 therefore	 physically	 meaningful	
calculation.	The	others	(the	blue	dots)	are	quasi	random	spectra.	In	
the	ordinate	the	similarity	between	the	computational	spectra	and	
the	 quantum	 chemical	 one	 is	 presented,	 where	 100%	 means	
perfect	similarity,	-100%	means	perfect	similarity	with	the	quantum	
chemical	 spectrum	 of	 the	 enantiomer	 and	 0%	 means	 complete	
dissimilarity.	 On	 the	 abscissa	 the	 similarity	 between	 each	
computational	 spectrum	 and	 the	 experimental	 spectrum	 is	
represented.	The	key	to	a	good	AC	assignment	is	that	the	quantum	
chemical	spectrum	(the	red	dot)	must	have	a	high	similarity	to	the	
experiment	 (here	 59%)	 and	 the	 blue	 ones	 must	 have	 a	 poorer	
similarity	to	the	experimental	spectrum.	
	 	
Figure	 4.	 Experimental	 VCD	 spectrum	 for	 3	 derived	 from	 (+)-
enantiomer	 1	 (lower	 panel)	 and	 the	 computed	 one	 for	 the	
(11S,12R)-absolute	configuration	(upper	panel).	
More	 specifically,	 the	 worse	 the	 similarity	 with	 the	 quantum	
chemical	spectrum,	the	worse	the	agreement	with	the	experiment.	
This	 is	 clearly	 the	case	here.	The	cloud	of	blue	dots	 stretches	as	a	
fairly	narrow	elongated	cloud	along	 the	bisector.	As	per	 reference	
34,	the	assignment	can	be	considered	very	trustworthy.	
Additional	 calculations	 were	 performed	 using	 large	 basis	 sets	
including	 aug-cc-pVTZ,	 the	 B3PW91	 functional,	 and	 Grimme	 D3	
empirical	 corrections	 for	 dispersion.34	 The	 calculations	 confirmed	
the	 assignment	 reported	 above,	 but	 did	 not	 further	 improve	
agreement	between	the	experiment	and	theory.	
The	 experimental	 and	 calculated	 spectra	 for	3	 obtained	 using	 the	
B3LYP/PCM/cc-pVDZ	method	 are	 shown	 in	 Figure	 4.	 A	manual	 AC	
assignment	 reveals	 a	 very	 tight	 correlation	 with	 the	 (11S,12R)-
configuration,	major	discrepancies	between	experiment	and	theory	
being	almost	exclusively	related	to	differences	in	relative	intensity.	
The	numerical,	 unbiased	analysis	 (see	ESI)	 supports	 the	 claim	 that	
the	analyzed	 compound	has	 the	 (11S,12R)-configuration.	Only	 few	
random	VCD	spectra	are	able	to	outperform	our	quantum	chemical	
spectrum	at	reproducing	the	experimental	one.	That	some	spectra	
can	be	slightly	better	is	to	be	expected	for	a	normal	distribution	and	
given	 the	 fact	 that	 no	 quantum	 chemical	 calculation	 can	 be	
expected	 to	 100%	 reproduce	 experiment	 due	 to	 inherent	
deficiencies	 in	 describing	 all	 intricate	 aspects	 of	 nature.	 The	 plot	
therefore	 reflects	 that	 assigning	 compound	 3	 to	 (11S,12R)	 is	 very	
robust,	which	is	consistent	with	results	obtained	with	XRD		
Given	 the	 fact	 that	 previous	 works	 repeatedly	 contradicted	 each	
other	 concerning	 the	 AC	 of	 (+)-erythro-mefloquine	we	 decided	 to	
independently	 repeat	 single	 crystal	 XRD	 studies.	 Our	 above	 VCD	
based	assignment	agrees	with	previous	XRD	work11	but	in	order	to	
improve	 the	 reliability	 of	 the	 XRD	 data,	 we	 also	 performed	 XRD	
measurements	 of	 compounds	3	 and	4	 which	were	 prepared	 from	
(+)-mefloquine	1	and	(-)-mefloquine	2,	respectively.	The	advantage	
is	the	presence	of	a	heavier	atom	and	thus	better	scatterer	of	the	x-
rays.	 As	 mentioned	 above,	 the	 sign	 of	 specific	 rotation	 changed	
upon	derivatization.	The	absolute	configuration	obtained	from	XRD	
analysis	 (Figure	6)	 for	the	(-)-thiourea	derivative	3	was	assigned	as	
(11S,	 12R)	 and	 the	 absolute	 configuration	 of	 the	 (+)-thiourea	
derivative	4	was	assigned	as	(11R,	12S).	Given	the	reported	change	
in	sign	of	the	optical	rotation,	we	may	conclude	that	our	VCD	based	
assignment	 for	 (+)-erythro-mefloquine	 is	 correct	 and	 the	 AC	 is	
therefore	finally	established.	
	
Figure	 5.	 XRD	 structures	 of	 (-)-erythro-N-(N-allylthiocarbamoyl)	
mefloquine	 (3)	with	 absolute	 configuration	 assigned	 as	 (11S,	 12R)	
and	 (+)-erythro-N-(N-allylthiocarbamoyl)	 mefloquine	 (4)	 with	
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absolute	 configuration	 (11R,	 12S).	 Acetonitrile	 is	 a	 crystal	 solvent;	
mirror	plane	is	assigned	as	m.		
The	ambiguity	in	the	determination	of	the	absolute	configuration	of	
(+)-erythro-mefloquine	 and	 its	 enantiomer,	 as	 a	 racemic	 mixture	
constituting	 an	 important	 antimalarial,	 has	 been	 resolved	 using	
Vibrational	 Circular	 Dichroism	 (VCD)	 spectroscopy.	 The	 absolute	
configuration	 of	 both	 enantiomers	 was	 assigned	 on	 the	 basis	 of	
thorough	 statistical	 analysis	 of	 the	 VCD	 spectra	 and	 then	
independently	confirmed	by	single	crystal	x-ray	diffraction	of	heavy	
atom	labeled	derivates.	
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